Study Of ATRN-119 In Patients With Advanced Solid Tumors
The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in patients with advanced solid tumors.
Advanced Solid Tumor
DRUG: ATRN-119
Treatment Emergent Adverse Events (TEAEs) will be collected and evaluated based on summary statistics, Treatment-emergent AEs (TEAEs) will be collected and Clinical Laboratory Evaluations will be performed, Day 1 to Day 28
The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in patients with advanced solid tumors.